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Abstract: Adenoid cystic carcinoma of Bartholin glands (BG-ACC) is a rare, slow-growing but a highly aggressive 
tumor with remarkable capacity for local recurrence and distant metastasis. The purpose of this study was to eluci-
date our experiences of the diagnosis and treatment of BG-ACC and to analyze the clinical outcomes and prognosis 
of patients with BG-ACC. A retrospective chart review was performed to assess the demographic information, chief 
complaints, pathologic features of tumors, primary treatment, and development of local recurrence or distant me-
tastasis, as well as the patient outcome. All patients received surgical excision as the primary treatment, and the 
diagnosis of BG-ACC was confirmed histopathologically. Three of four patients whose tumors showed pathologic 
features indicating a high probability of recurrence received adjuvant radiotherapy. These patients did not develop 
local recurrence, in contrast, one patient who did not receive adjuvant radiotherapy developed local recurrence 
and distant metastasis on several occasions. All patients who received primary surgical treatment are alive to date. 
When patients who are more than 40 years of age and who present with symptomatic BG lesions, BG-ACC should 
be included in the differential diagnosis and biopsy should be performed for histopathologic confirmation. Radical 
local excision with sufficient negative margins seems to be beneficial for primary treatment. Adjuvant radiotherapy 
is a reasonable treatment option for patients with high risk factors after surgery or for patients who develop local 
recurrence.
Keywords: Bartholin glands, adenoid cystic carcinoma, treatment, surgery, vulvar cancer
Introduction
Primary carcinoma of the Bartholin glands (BG), 
first documented by Klob [1] in 1864, is a rare 
malignancy comprising less than 1% of all 
female genital tract malignancies. Adeno- 
carcinomas and squamous cell carcinomas 
each account for approximately 40% and ade-
nosquamous carcinomas account for approxi-
mately 5% of BG carcinomas [2]. Adenoid cystic 
carcinoma of BG (BG-ACC) is a rare variant of 
BG carcinoma, comprising 15% of all BG malig-
nancies [3, 4]. BG carcinoma has no distin-
guishing clinical manifestations; hence, it is not 
easy to suspect or diagnose it during clinical 
practice. As a result, most primary BG carcino-
mas are often misdiagnosed and mistreated as 
BG cysts or abscesses. Because ACC in particu-
lar is even rarer, it is very difficult for clinicians 
to suspect it. Nevertheless, it is clinically very 
important since ACC has a high local recurrence 
rate and a tendency for distant hematogenous 
metastasis. Additionally, perineural invasion is 
common in ACC, and it is known to show local 
recurrence frequently even after securing a 
negative resection margin [5].
ACC is generally considered as a variant of vul-
var cancer; hence, surgical treatment is often 
performed based on the treatment guideline for 
primary squamous cell carcinoma of the vulva. 
Anatomically, however, it arises in tissues that 
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are different from the vulva, as the BG is locat-
ed within the subcutaneous tissue of the poste-
rior labia [6]. Since no prospective and random-
ized controlled trial for determining the optimal 
treatment modality for ACC exists, until now 
there is no consensus on the standard 
treatment. 
The purpose of this study was to elucidate our 
experiences of the diagnosis and treatment of 
BG-ACC and to analyze the clinical outcomes 
and prognosis of BG-ACC patients treated in a 
single institution.
Patients and methods
Between January 2001 and December 2014, 
five patients were diagnosed with BG-ACC at 
the Obstetrics and Gynecology, Samsung 
Medical Center (Seoul, Republic of Korea). A 
retrospective chart review was performed to 
assess the demographic information, chief 
complaints, pathologic features of tumors, pri-
mary treatment modality, the development of 
local recurrence, the presence of lymph node 
and/or distant metastasis, performance scale 
(based on the ECOG/WHO/Zubrod scoring sys-
tem), and the outcome of patients. As a preop-
erative work-up, abdomino-pelvic magnetic 
resonance imaging, chest computed tomogra-
phy (CT), and/or whole body positron emission 
tomography-CT scans were performed. 
In all cases, the diagnosis of primary or recur-
rent BG-ACC was confirmed histopathologically. 
All cases satisfied the diagnostic criteria for 
both BG carcinoma and BG-ACC. Firstly, the 
diagnostic criteria for primary BG carcinoma 
established by Finan et al. [7] were as follows: 
correct anatomic location of the tumor, with a 
primary location deep in the labia, intact overly-
ing skin, the presence of normal glandular ele-
ments on histology (Figure 1A), and no evi-
dence of a concurrent primary tumor elsewhere 
[8]. Secondly, the diagnostic criteria for BG-ACC 
described in the current WHO Classification 
were as follows: rounded and cribriform islands 
of uniform epithelial cells present within hya-
line stroma composed of basement membrane 
material [2]. This study was performed in accor-
dance with the ethical standards laid down in 
the 1964 Declaration of Helsinki and its later 
amendments. All patients gave their informed 
consent prior to their inclusion in this study.
Results
The clinical profiles and pathologic features are 
described in Table 1. The median age at diag-
nosis was 59 years (range, 50-67 years). The 
youngest patient was premenopausal. Patient 
4 had received right hemicolectomy with left 
lateral segmentectomy of the liver ten years 
ago due to ascending colon cancer with hepatic 
metastasis. After 12 cycles of adjuvant chemo-
therapy, no recurrence has been reported dur-
ing the follow-ups to date. Patient 5 had a previ-
ous history of marsupialization of BG abscess 
performed 8 months before the diagnosis of 
BG-ACC. All patients complained of a palpable 
mass near the BG area, and 4 patients had 
accompanying pain. Preoperative imaging stud-
ies showed no evidence of inguinal lymph node 
metastasis or distant metastasis in all patients, 
indicating that the BG-ACCs were localized 
lesions at diagnosis. 
As the primary treatment, radical local excision 
(n=4) or radical hemivulvectomy (n=1) was per-
Figure 1. Microscopic findings of BG-ACC. A. At low power magnification, an infiltrated tumor tissue (center and right 
one-third), the adjacent normal glands and ducts (black arrowheads) were observed. B. BG-ACC exhibited cribriform 
nests of small uniform tumor cells forming gland-like spaces with basement membrane-like material. C. Note peri-
neural invasion with tumor cell nests surrounding a nerve fiber (black arrow). 
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Table 1. Clinicopathological features and outcomes of 5 patients with a surgically resected BG-ACC
Patient Age Tumor laterality
Tumor 
size (cm)
Preoperative imaging study
Primary  
treatment
Pathologic features
Local 
recurrence
Distant 
metastasis
Outcome
Lymph node 
metastasis
Distant 
metastasis
RM 
status
Lymph node 
metastasis
Perineural 
invasion
Follow-up 
time (mo) Status PS
1 54 Right 2.0 Absent Absent RLE+IILND+ARTx Positive Absent Present Absent Present 71 SD 1
2 67 Left 2.5 Absent Absent RLE+ARTx Positive NA Present Absent Absent 106 NED 1
3 50 Left 1.0 Absent Absent RHV+IILND+ARTx Negative Absent Present Absent Absent 137 NED 1
4 60 Left 3.0 Absent Absent RLE Positive NA Present Present Present 224 PD 2
5 59 Right 4.0 Absent Absent RLE+IILND Negative Absent Present NA NA Recent case
RLE: radical local excision; IILND: ipsilateral inguinal lymph node dissection; ARTx: adjuvant radiotherapy; RHV: radical hemivulvectomy; RM: resection margin; NA: not applicable; SD: stable disease; NED: no 
evidence of disease; PD: progressive disease; PS: performance scale.
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formed. Ipsilateral inguinal lymphadenectomy 
was performed in three patients. Average tumor 
size was 2.5 cm in the longest diameter (range, 
1.0-4.0 cm). Microscopically, all cases of 
BG-ACC exhibited a classical cribriform arrange-
ment of tubules and gland-like elements (Figure 
1B). We examined the presence of several 
pathologic features indicating aggressive onco-
genic behavior (i.e., high-risk factors), including 
the involvement of surgical resection margin, 
inguinal lymph node metastasis, lymphovascu-
lar invasion, and/or perineural invasion (Figure 
1C). Involvement of the resection margin was 
observed in three patients (Patients 1, 2, and 
4). Three patients who received ipsilateral 
inguinal lymphadenectomy had no lymph node 
metastasis. Perineural invasion was observed 
in all patients. Among the four patients who 
had more than one high-risk factors (Patients 
1, 2, 3, and 4), postoperative adjuvant radio-
therapy was applied to three patients except for 
Patient 4. Recurrence of tumor was identified in 
two patients (Patients 1 and 4).
The outcomes of patients with BG-ACC were 
also assessed (Table 1). The mean survival 
time except for that in one patient (Patient 5, 
recent case) was 134.5 months (range, 71-214 
months). All patients are alive to date. According 
to the RECIST classification, two patients 
(Patients 2 and 3) were classified as having ‘no 
evidence of disease’, one (Patient 1) was classi-
fied as having ‘stable disease’, and one (Patient 
4) was classified as having ‘progressive 
disease’. 
The clinical features of two patients who devel-
oped local recurrences and/or distant metasta-
ses are summarized in Table 2. Despite show-
ing resection margin involvement Patient 4 did 
not receive adjuvant radiotherapy. She devel-
oped local recurrence in the vulva, perineal 
area, and pelvic cavity on 4 occasions, and dis-
tant metastasis to the lung and liver on 5 occa-
sions both after the first surgery. Especially 
after the first recurrence, active treatments 
such as surgery and/or palliative chemotherapy 
were performed, but local recurrence and dis-
tant metastasis occurred subsequently. At 
present, we are only performing conservative 
management such as pain control. Patient 1 
developed pulmonary metastases twice at 7 
and 8 months after radical local excision with 
adjuvant radiotherapy. Patient 1 received 
metastasectomy with subsequent chemothera-
py (paclitaxel and carboplatin) for the first 
metastasis, and metastasectomy only for the 
second metastasis. Regardless of the active 
treatment similar to that in Patient 4, it was 
impossible to remove pulmonary lesions com-
pletely. However, no local recurrence has 
occurred to date, and the number and the size 
of residual pulmonary lesions have not 
increased. 
Discussion 
BG-ACC is extremely rare, with only about 80 
cases having been reported in the literature [5]. 
This study reported the highest number of 
cases of BG-ACC alone at a single institution. 
Clinical manifestation of BG-ACC is not largely 
different from that of vulvar cancer, which 
shows different histology. Patients with a mass 
around the BG usually complain of an abnormal 
sensation along with a palpable mass (or cyst) 
Table 2. Clinical features of 2 patients with recurrent or metastatic BG-ACC
Patient Disease progression Months after 
the first surgery
Tumor location Treatment
1 Distant metastasis 7 Lung Metastasectomy
Recurrent metastasis 8 Lung Metastasectomy +PCTx
4 Local recurrence 24 Vulva RLE
Local recurrence 46 Vulva RLE
Local recurrence 60 Pelvic peritoneum, vagina, and urethra RH+PE+BIFLND
Distant metastasis 71 Lung Metastasectomy +PCTx
Distant metastasis 132 Liver CTx+ hemihepatectomy
Recurrent metastasis 179 Lung Conservative
Local recurrence 182 Perineal area and pelvic peritoneum Conservative
Recurrent metastasis 189 Lung Conservative
PCTx: palliative chemotherapy; RLE: radical local excision; RH: radical hysterectomy; PE: pelvic exenteration; BIFLND: bilateral 
inguinofemoral lymph node dissection; CTx: chemotherapy.
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with or without pain, pruritus, or skin discolor-
ation etc. It is presumed to be related to peri-
neural invasion, which is a characteristic of 
BG-ACC but not a unique feature of BG-ACC. 
Therefore, most symptomatic BG masses are 
diagnosed as BG cysts or abscesses, and they 
are managed only by incision and drainage. 
However, some cases among those, in which 
only marsupialization was performed, are likely 
to be of BG carcinoma. In this study, we con-
firmed that when Patient 5 visited our institu-
tion with a BG mass 8 months ago, we suspect-
ed it to be a BG cyst and only performed marsu-
pialization without biopsy. We cannot exclude 
the possibility of the BG mass (which was found 
8 months after marsupialization) being a newly 
developed BG-ACC, but there is a possibility 
that BG-ACC was misdiagnosed as a BG cyst, 
which resulted in belated treatment. In this 
respect, number of researchers have recom-
mended cytologic examination through fine-
needle aspiration in women who are 40 years 
of age or older [9, 10]. However, cytology has 
low diagnostic value and morbidity related to 
the procedure increases in case of radical pro-
cedure such as BG cystectomy. Thus, it can be 
considered that in case of a symptomatic BG 
cyst, incisional or excisional biopsy is neces-
sary to exclude the presence of a hidden carci-
noma after draining the cyst. 
Because BG-ACC is a slow-growing tumor, it is 
known to be apt to invade locally. Perineural 
invasion, which is a histologic characteristic of 
ACC, is also one of the reasons that explain its 
frequent recurrences. Moreover, there are 
reports that even after initial surgical excision, 
regardless of the existence of resection margin 
involvement (in other words, after securing a 
negative resection margin,) it recurs at the end 
[11]. On the other hand, distant metastasis 
generally occurs after a long time since the ini-
tial diagnosis. When we refer to previous stud-
ies, it seems that even after the first recur-
rence, BG-ACC patients stay alive for a consid-
erable amount of time [12]. The rate of local 
recurrence and distant metastasis of BG-ACC 
is estimated to be 30% and 31%, respectively 
[9]. One study reported that the overall survival 
rates of patients with BG-ACC for 5 and 10 
years range from 71% to 100% and 59% to 
100%, respectively [11]. Another study showed 
that the progression-free survival rate was 47% 
at 5 years and 35% at 10 years, respectively, 
and that the overall survival rate was 71% and 
59% at 5 and 10 years, respectively [9]. In this 
study, Patient 4 who did not receive adjuvant 
radiotherapy showed metastatic lesions in the 
lung and liver on several occasions, but it did 
not lead to her death. This proves that BG-ACC 
is a slow-growing tumor although it shows 
aggressive behavior, and further investigation 
on survival is necessary. 
The most preferred primary treatment is surgi-
cal excision. Various surgical options include 
local or wide local excision, radical local exci-
sion, and radical hemivulvectomy, with or with-
out ipsilateral inguinofemoral lymphadenecto-
my. An important point about the surgery is that 
wide excision is crucial in order to secure a 
pathologically sufficient negative resection 
margin. The reason for this is that BG carcino-
ma tends to extend towards the lateral wall of 
the vagina as well as towards the ischiorectal 
fossa. Thus, partial excision of the levator ani 
muscle and/or distal vagina may be necessary 
when we consider various clinical situations. 
However, radical vulvectomy should not be uni-
versally applied because recurrence rates are 
similar in patients with positive and negative 
resection margins, explained in part by adju-
vant radiation therapy being preferentially pro-
posed in case of inadequate margin status [1]. 
Accordingly, this study suggests that adjuvant 
radiotherapy may be beneficial in reducing local 
recurrence. Three patients who had resection 
margin involvement and perineural invasion 
received adjuvant radiotherapy, and no local 
recurrence was found during the follow-up. 
Among them, one patient developed pulmonary 
metastasis. On the other hand, one patient who 
showed resection margin involvement but did 
not receive adjuvant radiotherapy developed 
local recurrence on several occasions, and 
despite repeated surgery, the tumor extended 
to the pelvic peritoneum. Eventually, radical 
hysterectomy and pelvic exenteration was per-
formed, but the tumor recurred again in residu-
al perineal tissues. In the future, researches 
assessing the efficacy and safety of adjuvant 
radiotherapy are necessary. However, perform-
ing adjuvant radiotherapy in patients who pres-
ent with pathologic features which indicate 
aggressive oncogenic behavior is thought to be 
beneficial in reducing the local recurrence as of 
now. Rosenberg et al. [8] and Copeland et al. 
[9] have reported the benefits of postoperative 
external beam radiation in patients with posi-
tive surgical margins. They performed adjuvant 
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radiotherapy in 15 patients with BG-ACC, and 
no local recurrence occurred after the treat-
ment. This study indicates that adjuvant radio-
therapy may reduce the incidence of local 
recurrence. 
The frequency of microscopically positive surgi-
cal resection margin is relatively high. Therefore, 
it is reported that approximately 40% of 
patients need adjuvant radiotherapy after pri-
mary surgery [8, 9, 13]. In a previous study, pri-
mary radiotherapy or chemotherapy was per-
formed in 10 patients with BG carcinoma [6]. 
Treatment options included teletherapy com-
bined with a boost to the primary site, regional 
nodes and/or interstitial brachytherapy. The 
median follow-up period was 87.2 months 
(range, 45-142 months). Three- and five-year 
survival rates were 71.5% and 66%, respective-
ly, comparable to outcomes after surgery and 
postoperative radiotherapy. This indicates that 
primary nonsurgical treatment might provide 
an effective alternative to surgery with preser-
vation of genital function and low morbidity. 
No lymph node metastasis was found in this 
study before and after the primary treatment. It 
is known that inguinal lymph node metastasis 
rarely occurs in BG-ACC patients and even if it 
does, it occurs ipsilateral to the primary tumor. 
However, the prognostic and therapeutic value 
of lymphadenectomy is unclear in the 
literature. 
Lung is the most common site of distant metas-
tasis of BG-ACC [5]. In unusual cases, metasta-
sis has been reported to occur in the brain, kid-
ney, and liver [14, 15]. There is not much infor-
mation on treatment of metastasis and it var-
ies according to the location of the metastasis. 
In metastatic ACC, chemotherapy has been 
used; but there are few researches assessing 
the effectiveness of chemotherapy to date. The 
aim of the treatment is palliation. Several che-
motherapeutic regimens have been evaluated 
in the literature, but cyclophosphamide, adria-
mycin, and cisplatin regimen seems to be used 
relatively frequently. A previous study reported 
that after the administration of 5-fluorouracil, 
adriamycin, and mitomycin in a patient with 
metastatic ACC of the salivary gland, the tumor 
showed complete remission [16]. In another 
study, a combination of methotrexate, dactino-
mycin, chlorambucil, adriamycin, and cyclo-
phosphamide was administered in a patient 
with metastatic BG-ACC [11, 13]. In this study, 
we performed 6 cycles of adriamycin and cispl-
atin in Patient 1 who developed pulmonary 
metastasis, and the patient has achieved sta-
ble disease status until now. In Patient 4, local 
recurrence occurred on three occasions and 
pulmonary metastasis developed subsequent-
ly. In the follow-up after surgery, the tumor 
showed progression; hence, we performed pal-
liative chemotherapy with 6 cycles of cyclo-
phosphamide, adriamycin, and cisplatin. After 
this, metastasis to the liver occurred; hence, 4 
cycles of palliative chemotherapy with ifos-
famide as a single agent were performed. 
However, the effect was not satisfactory. 
BG-ACC is a very rare malignancy of the vulva. 
Local recurrence and distant metastasis have 
been commonly reported. This study has taken 
a very small number of patients into account. 
Nevertheless, when we consider that ACC 
develops very rarely in the BG, we think that our 
clinical experience can help to determine its 
clinical course and prognosis. As in the case of 
other tumors, a prospective randomized study 
can provide the most powerful evidence for 
deciding the optimal treatment. However in 
reality, it is very difficult to perform such a large 
study of extremely rare diseases. In this 
respect, collaborative multicenter data collec-
tion is crucial and the accumulated information 
will provide a strong basis for long-term progno-
sis, overall and recurrence-free survival rates, 
and identifiable surgical risk factors. It will also 
contribute to provide necessary evidence for 
deciding the optimal treatment modality.
Finally, in order to prevent misdiagnosis and 
mistreatment, we propose that in case of a 
symptomatic cyst or mass in the BG area in a 
patient of age 40 years or older, ACC must be 
included in the differential diagnosis. A patho-
logical diagnosis through a biopsy is critical. As 
a primary treatment, radical local excision 
should be performed for securing a sufficient 
resection margin. If there are high risk factors, 
performing adjuvant radiotherapy seems to be 
the optimal treatment of choice as of now. 
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